Document Detail

The discovery and development of rivaroxaban.
MedLine Citation:
PMID:  21434944     Owner:  NLM     Status:  In-Data-Review    
Thromboembolic conditions present a considerable challenge to healthcare services because they are associated with substantial morbidity and mortality. The mainstays of prevention and treatment are anticoagulants and antiplatelet agents. Established anticoagulants have drawbacks that make their use difficult to manage and sustain. This has stimulated the search for new oral anticoagulants that are more convenient and yet still effective. This paper describes the development and future potential of rivaroxaban (Xarelto™; Bayer Schering Pharma AG, Berlin, Germany)-the first oral, direct Factor Xa inhibitor to be approved for clinical use in the prevention of venous thromboembolism in adult patients undergoing elective hip or knee replacement surgery.
Frank Misselwitz; Scott D Berkowitz; Elisabeth Perzborn
Related Documents :
12010594 - Topical steroid therapy for phimosis.
24913684 - Long-term outcomes and sac volume shrinkage after endovascular popliteal artery aneurys...
24623184 - Five-year survivorship and patient-reported outcome of the triathlon single-radius tota...
24790404 - Intracameral air following pneumatic noncontact tonometry in a recently post-perforatin...
18382424 - Is sitaxsentan a good therapeutic option for pulmonary arterial hypertension associated...
24250334 - Efficacy of onabotulinum toxin a (botox) versus abobotulinum toxin a (dysport) using a ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Annals of the New York Academy of Sciences     Volume:  1222     ISSN:  1749-6632     ISO Abbreviation:  Ann. N. Y. Acad. Sci.     Publication Date:  2011 Mar 
Date Detail:
Created Date:  2011-03-25     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7506858     Medline TA:  Ann N Y Acad Sci     Country:  United States    
Other Details:
Languages:  eng     Pagination:  64-75     Citation Subset:  IM    
Copyright Information:
© 2011 New York Academy of Sciences.
Therapeutic Area Cardiovascular and Coagulation, Global Clinical Development, Bayer HealthCare AG, Wuppertal, Germany. Thrombosis and Hemostasis Group, Cardiovascular and Coagulation Therapeutic Area, Global Clinical Development, Bayer HealthCare Pharmaceuticals, Montville, New Jersey. Bayer HealthCare Pharmaceuticals, Cardiovascular Pharmacology, Global Therapeutic Research, Bayer HealthCare AG, Wuppertal, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The development of romiplostim for patients with immune thrombocytopenia.
Next Document:  A review of the history, properties, and use of the immunomodulatory compound lenalidomide.